Genix Pharmaceuticals Corporation
GENPF
$0.01
-$0.02-53.00%
OTC PK
| 01/31/2026 | 10/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -29.60% | -5.51% | |||
| Depreciation & Amortization | -- | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -30.22% | -5.46% | |||
| Operating Income | 30.22% | 5.46% | |||
| Income Before Tax | 42.71% | -9.38% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 42.71% | -9.38% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 42.71% | -9.38% | |||
| EBIT | 30.22% | 5.46% | |||
| EBITDA | -- | 5.51% | |||
| EPS Basic | 45.45% | -10.00% | |||
| Normalized Basic EPS | 33.33% | 0.00% | |||
| EPS Diluted | 45.45% | -10.00% | |||
| Normalized Diluted EPS | 33.33% | 0.00% | |||
| Average Basic Shares Outstanding | 1.20% | 2.15% | |||
| Average Diluted Shares Outstanding | 1.20% | 2.15% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||